Federal enforcement officials delivered some of their clearest messages yet to the life sciences industry at this year’s Pharmaceutical Compliance Congress (PCC) in McLean, Virginia, signaling that 2026 will bring more aggressive oversight, broader scrutiny, and heightened expectations for corporate accountability.
Speaking to an audience of compliance officers, inâhouse counsel,